Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28975535 | 0.83 | ACHE (0.49) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL24169402 | 0.81 | NCOA1 (0.40) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL21593327 | 0.81 | PARP10 (0.47) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL16246496 | 0.79 | ATM (0.50) | NCOA1NCOA3KDM4EALDH1A1 | |
| SCHEMBL609771 | 0.78 | PARP10 (0.50) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL22491102 | 0.78 | NCOA1 (0.38) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL23193539 | 0.78 | NCOA1 (0.38) | NCOA1NCOA3PARP10PARP1GRM5 | |
| SCHEMBL19667257 | 0.77 | TUBB4A (0.46) | KDM4EALDH1A1MAPTHPGDBRD4 | |
| SCHEMBL22713749 | 0.76 | PARP10 (0.47) | PARP10PARP1GRM5PARP11KDM4E | |
| SCHEMBL16964597 | 0.76 | PARP10 (0.47) | PARP10PARP1GRM5PARP11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3464249-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | NCOA1 1156/4885NCOA3 785/4885PARP10 330/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | NCOA1 1156/4885NCOA3 785/4885PARP10 330/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | NCOA1 1156/4885NCOA3 785/4885PARP10 330/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | NCOA1 1156/4885NCOA3 785/4885PARP10 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.